GSS and MAP agree to Commercial Terms for Merger

Key points

• Complementary diagnostic technologies and expanded market access
• Microba shareholders to receive 0.654 new GSS shares for each MAP share
• Estimated annualised gross cost synergies of $2.5 - 3.0 million

Full summary

Genetic Signatures Limited (ASX: GSS) and Microba Life Sciences Limited (ASX: MAP) have agreed on the principal commercial terms for a merger. The merger aims to combine two Australian diagnostics businesses with complementary technologies, products, and international distribution networks. Under the terms, Microba shareholders will receive 0.654 new GSS shares for each MAP share, with Microba shareholders holding approximately 67% of the enlarged group. The merger is expected to create a stronger diagnostics group with an expanded international commercial platform, broader product portfolio, and greater financial and operational scale.

Outlook

The merger is expected to create a differentiated diagnostics group capable of addressing a broader range of clinical testing requirements and leveraging the respective customer relationships, distribution networks, and regulatory capabilities of the two businesses.